Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DARE-PTB1 is an investigational intravaginal ring (IVR) designed to deliver bio-identical progesterone continuously for up to 14 days. It is being developed by Daré Bioscience as a treatment to reduce the risk of preterm birth in at-risk women—a significant unmet need as there are currently no FDA-approved therapies specifically for this indication. The device uses sustained-release technology to provide a non-oral alternative to daily progesterone injections or gels and may also be investigated for luteal phase support in IVF regimens. The product leverages the same IVR platform used in other Daré programs and aims to offer improved convenience and adherence compared with existing options[1][3][5][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DARE-PTB1.